Media Coverage

Researchers from ISB’s Wei and Heath labs show that cancer cells can quickly reprogram themselves in response to treatment, using epigenetic changes to survive drugs — revealing that resistance may begin much earlier than previously understood.

ISB’s Dr. Wei Wei contributed to research showing that certain lung cancers can shift identity and exist in hybrid states, helping explain treatment resistance and suggesting new approaches to diagnosis and therapy for these aggressive, often underdiagnosed tumors.

Research from ISB’s Gibbons Lab suggests bowel movement frequency is linked to overall health, with a “Goldilocks zone” of about one to two per day. Too few or too many may be associated with risks to kidney, liver, and metabolic health.

A new study finds that a gut bacterium may contribute to memory loss in mice, highlighting growing evidence of connections between the microbiome and brain health. ISB’s Sean Gibbons discusses the study’s implications.

This profile details Lee Hood and his decades-long mission to transform medicine through systems biology and predictive health. Hood outlines how large-scale biological data and longitudinal studies could enable earlier detection of disease and more proactive healthcare.

ISB researchers are using advanced computer simulations of the gut microbiome to explore how probiotics interact with existing microbial communities. The work highlights how modeling approaches can help predict when probiotic strains are likely to thrive — and when they may fail to take hold.

A new SELF feature highlights research showing that bowel movement frequency — particularly one to two times per day — may be linked to overall health, including gut microbiome balance and toxin levels. ISB’s Sean Gibbons explains why this “Goldilocks zone” could signal optimal physiology.

Researchers in the Gibbons Lab used computer models of gut metabolism to predict which probiotic strains will successfully establish in an individual’s microbiome and how prebiotics influence beneficial molecule production, a step toward more personalized microbiome-based interventions.